Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More

JAMA. 2023 Dec 19;330(23):2237-2240. doi: 10.1001/jama.2023.22707.
No abstract available

Plain language summary

This Medical News article discusses late-breaking science and other clinical highlights from the American Heart Association’s Scientific Sessions meeting.

MeSH terms

  • American Heart Association
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Glucagon-Like Peptide-1 Receptor Agonists* / therapeutic use
  • Glucagon-Like Peptides / therapeutic use
  • Humans
  • Risk Assessment
  • United States

Substances

  • Glucagon-Like Peptides
  • semaglutide
  • Glucagon-Like Peptide-1 Receptor Agonists